Haleon plc (HLNCF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 18.50 means the share price is 18.50 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $40.1B is the value of all shares combined. Beta 0.25: the stock has moved about 75% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHaleon plc (HLNCF) trades at $4.55. Haleon plc is a global consumer healthcare company that develops, manufactures, and sells a wide range of over-the-counter products. Market cap: $40.1B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for HLNCF: HLNCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLNCF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
HLNCF: 1/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Haleon plc (HLNCF) Healthcare & Pipeline Overview
Haleon plc is a global leader in consumer healthcare, offering a diverse portfolio of trusted brands like Panadol and Sensodyne. Operating in a stable, yet competitive market, Haleon leverages its brand recognition and distribution network to maintain its position in the over-the-counter drug market.
What Is the Investment Thesis for HLNCF?
With a market capitalization of $40.1B and a profit margin of 13.8%, the company demonstrates financial stability. Key growth drivers include increasing demand for OTC products, particularly in emerging markets, and the company's ability to innovate and launch new products. The dividend yield of 1.42% offers a steady return for investors. However, potential risks include competition from other major players in the consumer healthcare industry and regulatory changes affecting the OTC market. The company's low beta of 0.25 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
HLNCF Key Highlights
Market capitalization of $40.1B, reflecting a significant presence in the consumer healthcare market.
- Profit margin of 13.8%, indicating efficient operations and profitability.
- Gross margin of 61.8%, showcasing strong pricing power and cost management.
- Dividend yield of 1.42%, providing a steady income stream for investors.
- Low beta of 0.25, suggesting lower volatility compared to the overall market.
Who Are HLNCF's Competitors?
HLNCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| DSKYF Daiichi Sankyo Company, Limited | $17.65 | +0.51% | $32.1B | 559-signal |
| HOCPF HOYA Corporation | $144.21 | -7.56% | $48.2B | — |
| IPSEY Ipsen S.A. | $46.50 | 0.00% | $61.5B | — |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| SDZNY Sandoz Group AG | $81.08 | -2.68% | $35.1B | 519-signal |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| MKGAF Merck KGaA | $151.95 | -3.35% | $66.1B | 469-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are HLNCF's Key Strengths?
Strong brand portfolio with high consumer recognition.
- Global distribution network reaching diverse markets.
- Focus on innovation and new product development.
- Efficient operations and cost management.
What Are HLNCF's Weaknesses?
Dependence on a limited number of key brands.
- Exposure to regulatory changes in the OTC market.
- Competition from established players and generic brands.
- Potential for product recalls and liability issues.
What Could Drive HLNCF Stock Higher?
Expansion into emerging markets, driving revenue growth.
- New product launches and innovation in key therapeutic areas.
- Potential strategic acquisitions to expand product portfolio.
- Increasing demand for OTC products due to rising healthcare costs.
- Digital marketing and e-commerce initiatives to reach a wider audience.
What Are the Key Risks for HLNCF?
Intense competition from other major players in the consumer healthcare industry.
- Regulatory changes affecting the OTC market.
- Economic downturns affecting consumer spending.
- Adverse currency fluctuations.
- Dependence on a limited number of key brands.
What Are the Growth Opportunities for HLNCF?
- Expansion in Emerging Markets: Haleon has a significant opportunity to expand its presence in emerging markets, where demand for OTC products is growing rapidly due to increasing disposable incomes and rising healthcare awareness. By tailoring its product offerings to local needs and preferences, Haleon can capture a larger share of these markets. This expansion could contribute significantly to revenue growth over the next 3-5 years.
- New Product Development and Innovation: Investing in research and development to launch new and innovative products can drive growth for Haleon. Focusing on areas such as personalized healthcare and digital health solutions can attract new customers and differentiate the company from its competitors. Successful product launches can lead to increased sales and market share gains within the next 2-3 years.
- Strategic Acquisitions: Haleon can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring smaller companies with complementary products or technologies can provide access to new markets and customer segments. Synergies from acquisitions can lead to cost savings and increased profitability over the long term.
- Digital Marketing and E-commerce: Enhancing its digital marketing efforts and expanding its e-commerce presence can help Haleon reach a wider audience and drive online sales. Investing in targeted advertising and improving the online customer experience can increase brand awareness and customer loyalty. This strategy can generate significant revenue growth within the next 1-2 years.
- Focus on Sustainability: Consumers are increasingly concerned about the environmental and social impact of the products they buy. By focusing on sustainability and reducing its environmental footprint, Haleon can attract environmentally conscious consumers and enhance its brand reputation. Implementing sustainable practices can also lead to cost savings and improved operational efficiency over time.
What Are HLNCF's Competitive Advantages?
- Strong Brand Portfolio: Haleon owns a portfolio of well-known and trusted brands, such as Panadol, Sensodyne, and Advil, which have strong brand recognition and customer loyalty.
- Global Distribution Network: The company has a well-established global distribution network, allowing it to reach customers in various regions and markets.
- Innovation and Product Development: Haleon invests in research and development to launch new and innovative products, which helps it maintain a competitive edge.
- Scale and Efficiency: Haleon benefits from economies of scale and efficient operations, which allow it to offer competitive pricing and maintain profitability.
What Does HLNCF Do?
Haleon plc, incorporated in 2021 and headquartered in Brentford, United Kingdom, is a consumer healthcare company that researches, develops, manufactures, and sells a variety of over-the-counter (OTC) products. Spun out to become its own entity in early 2022 (formerly known as DRVW 2022 plc), Haleon's origins trace back to the consumer health divisions of pharmaceutical giants. The company's portfolio includes well-known brands across several therapeutic categories, including oral health (Sensodyne, Polident, parodontax), pain relief (Panadol, Voltaren, Advil), respiratory health (Otrivin, Theraflu), digestive health, and vitamins, minerals, and supplements (Centrum). Haleon distributes its products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company focuses on innovation and brand building to maintain its competitive edge in the global consumer healthcare market. Haleon's strategy involves expanding its market share through strategic acquisitions, product development, and geographic expansion, catering to the evolving needs of consumers seeking accessible healthcare solutions.
What Products and Services Does HLNCF Offer?
- Researches and develops consumer healthcare products.
- Manufactures over-the-counter (OTC) medications and healthcare solutions.
- Sells a wide range of products including oral health, pain relief, respiratory health, and digestive health remedies.
- Offers vitamins, minerals, and supplements.
- Markets and distributes its products globally across various regions.
- Focuses on brand building and innovation to maintain a competitive edge.
- Adapts product offerings to meet the evolving needs of consumers.
How Does HLNCF Make Money?
- Develops and manufactures a diverse portfolio of consumer healthcare products.
- Distributes products through various channels, including pharmacies, retailers, and online platforms.
- Generates revenue through the sale of its branded products.
- Invests in marketing and advertising to build brand awareness and drive sales.
What Industry Does HLNCF Operate In?
Haleon operates in the global consumer healthcare market, which is characterized by increasing demand for over-the-counter (OTC) products and a growing emphasis on self-care. The market is competitive, with major players such as CHALF (Church & Dwight Co.) and DSNKY (Nestle) vying for market share. The industry is driven by factors such as an aging population, rising healthcare costs, and increasing awareness of preventive healthcare measures. Haleon's strong brand portfolio and global distribution network position it well to capitalize on these trends.
Who Are HLNCF's Key Customers?
- Individual consumers seeking over-the-counter healthcare solutions.
- Pharmacies and retailers that stock and sell Haleon's products.
- Healthcare professionals who may recommend Haleon's products to their patients.
- Online shoppers purchasing healthcare products through e-commerce platforms.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 438 days ago
- ● No analyst coverage
- ● Reported in GBP, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 49 |
| 2026-08-26 | 49 |
| 2026-08-29 | 49 |
| 2026-09-01 | 49 |
| 2026-09-04 | 49 |
| 2026-09-07 | 49 |
| 2026-09-10 | 49 |
What changed?
The score has stayed at 49.
Over the same 18 days the stock moved -5.5%.
Haleon plc Financial Trajectory
Haleon plc (HLNCF) reported $3.70B in revenue for Q2 FY2025, reflecting 0.0% growth compared to the prior quarter. The company recorded net income of $544.9M, with diluted EPS of $0.06. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, HLNCF averaged $0.06 in diluted EPS.
Company Profile
Haleon plc operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Weybridge, GB. The company is led by CEO Brian James McNamara. HLNCF has traded publicly since 2022.
How Haleon plc Is Valued
Haleon plc carries a market capitalization of $40.1B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for Haleon plc stands at 9.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.0%, showing how much profit it generates from its asset base. HLNCF trades at a trailing price-to-earnings ratio of 18.50, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.69 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Haleon plc's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.90 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Haleon plc has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 8.9% below estimates on average.
Forward Outlook
Wall Street analysts project Haleon plc revenue of about $11.54B for fiscal 2026, with EPS near $0.21. The estimate reflects 16 contributing analysts.
HLNCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong brand portfolio with high consumer recognition.
- Global distribution network reaching diverse markets.
- Focus on innovation and new product development.
- Efficient operations and cost management.
Bear Case
- Dependence on a limited number of key brands.
- Exposure to regulatory changes in the OTC market.
- Competition from established players and generic brands.
- Potential for product recalls and liability issues.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2025 | $3.70B | $545M | $0.06 |
| Q1 FY2025 | $3.70B | $545M | $0.06 |
| Q4 FY2024 | $3.73B | $312M | $0.03 |
| Q3 FY2024 | $3.76B | $656M | $0.07 |
Q2 FY2025 · filed 30 Jun 2025 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from GBP at today's rate
HLNCF Latest News
No recent news available for HLNCF.
HLNCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HLNCF.
Price Targets
Wall Street price target analysis for HLNCF.
HLNCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HLNCF; grades run from A+ (80-100) to F (below 30).
Leadership: Brian James McNamara
CEO
Brian James McNamara serves as the Chief Executive Officer of Haleon. His career spans various leadership roles within the consumer healthcare sector. Before Haleon became an independent entity, McNamara held key positions at GlaxoSmithKline (GSK), overseeing their consumer healthcare division. His experience includes global brand management, strategic planning, and operational execution. McNamara's expertise lies in driving growth through innovation, market expansion, and effective brand management. He is known for his strategic vision and ability to lead large, complex organizations.
Track Record: Under McNamara's leadership, Haleon has focused on strengthening its brand portfolio and expanding its presence in key markets. He has overseen the successful launch of new products and implemented strategies to improve operational efficiency. McNamara has also emphasized sustainability and corporate responsibility, aligning the company's goals with broader societal needs. His tenure has been marked by a commitment to innovation and customer-centricity.
HLNCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Haleon plc (HLNCF) may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not meet the minimum financial standards or disclosure requirements necessary for listing on higher-tier exchanges. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Limited regulatory oversight and reporting requirements.
- Lower trading volumes and wider bid-ask spreads.
- Potential for price volatility and manipulation.
- Increased risk of fraud or misrepresentation.
- Limited access to company information and financial disclosures.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading activity and price movements.
- Consult with a financial advisor before investing.
- Established brand portfolio with well-known products.
- Global presence and distribution network.
- History of operations as part of a larger corporation (GSK).
- Presence of experienced management team.
- Focus on innovation and new product development.
What Investors Ask About Haleon plc (HLNCF) — Healthcare
Is HLNCF a good stock?
Stock Expert AI does not rate HLNCF buy, sell or hold. Haleon plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about HLNCF stock?
Analyst coverage of HLNCF is still developing given its relatively recent spin-off and listing. Broadly, analysts recognize the company's strong brand portfolio and global reach as key strengths. Valuation metrics such as P/E ratio of 18.50 are being closely watched in relation to growth prospects and industry peers.
What are the key factors to evaluate for HLNCF?
Evaluate HLNCF on fundamentals, analyst consensus, and risk factors. P/E: 18.50x vs the S&P 500's ~20-25x. The dividend yield of 1.42% offers a steady return for investors. Not financial advice.
How frequently does HLNCF data refresh on this page?
HLNCF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HLNCF's recent stock price performance?
Haleon plc (HLNCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand portfolio with high consumer recognition. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLNCF overvalued or undervalued right now?
Haleon plc (HLNCF) trades at 18.50x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HLNCF?
Yes, most major brokerages offer fractional shares of Haleon plc (HLNCF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HLNCF's earnings and financial reports?
Haleon plc (HLNCF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for HLNCF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.